S24 - MS Therapeutics and Clinical Research I

Event Time: Tuesday April 25, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 Dimethyl fumarate treatment produces alterations in lipid metabolism that are linked to occurrence of lymphopenia Pavan Bhargava, MD
Disclosure:
Dr. Bhargava has nothing to disclose.

3:42 PM 002 Depletion of CD8+ cells in patients with multiple sclerosis on dimethyl fumarate and its association with shingles Ursela Siddiqui, MD
Disclosure:
Dr. Siddiqui has nothing to disclose.

3:54 PM 003 Ofatumumab Differs from Rituximab by Effectively Targeting Lymph Node B cells and Achieving Faster Post-treatment Repletion Paul Smith
Disclosure:
Dr. Leppert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Novartis Pharma AG.

4:06 PM 004 Ambulation Assistive Device Training Prevents Falls, Increases Device Satisfaction and May Decrease Sitting and Increase Walking in MS: A Randomized-Controlled Pilot Study Andrea Hildebrand
Disclosure:
Dr. Hildebrand has nothing to disclose.

4:18 PM 005 Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I) Barry Singer, MD
Disclosure:
Dr. Singer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, and Teva. Dr. Singer has received research support from Acorda, Alkermes, Biogen, MedImmune, Novartis, Roche, and Sanofi Genzyme.

4:30 PM 006 Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) Edward J Fox, MD, PhD, FAAN
Disclosure:
Dr. Fox has nothing to disclose.

4:42 PM 007 Fitness to drive in persons with MS and cognitive impairment: a pilot study Sarah Anne Morrow, MD, MSC,FRCPC
Disclosure:
Dr. Morrow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Genzyme, Novartis, Roche. Dr. Morrow has received research support from Novartis, Roche.

4:54 PM 008 Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis Jeffrey Cohen, MD
Disclosure:
Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adams and Celgene. Dr. Cohen has received personal compensation in an editorial capacity for Mult Scler J - ETC.

Register Now

Related Courses